Bristol Myers Squibb and Hengrui Pharma Strike $15.2B Drug Partnership, $600M Upfront Deal
Bristol Myers Squibb has partnered with China’s Hengrui Pharma in a $600 million upfront licensing deal covering over a dozen early-stage drug program...
Bristol Myers Squibb has partnered with China’s Hengrui Pharma in a $600 million upfront licensing deal covering over a dozen early-stage drug program...
Kelonia Therapeutics transformed from a struggling biotech startup into a $3 billion company. Discover how BioAge’s inflammation-focused strategy and...